The global trend toward aging populations has resulted in an increase in the occurrence of Alzheimer's disease (AD) and associated socio-economic burdens. Abnormal metabolism of amyloidâ β (Aβ) has been proposed as a signiï¬ cant pathomechanism in AD, supported by results of recent clinical trials using antiâ Aβ antibodies. Nonetheless, the cognitive beneï¬ ts of the current treatments are limited. The etiol...